Pharma News

Redox reactions play an important role in our everyday life. In these reactions, one compound releases electrons and is oxidized, while another accepts electrons and is reduced. Such redox reactions are exploited by living organisms, for example, to store energy.

A chromatin-regulating enzyme has been shown by in-depth interdisciplinary investigations to be a key driver of a common type of lung cancer. Drugs that target the enzyme could improve treatment and survival rates for this particular cancer.

Using the integrated approach of cheminformatics and network systems biology, Researchers from IIT Guwahati investigated Amalaki Rasayana (AR), an Ayurvedic rejuvenate for the treatment of cardiovascular diseases such as pressure-overload left ventricular cardiac hypertrophy (LVCH). The study has been published in the Nature Partnership Journal System Biology and Applications.

The National Botanical Research Institute (NBRI), a Lucknow-based constituent laboratory of the Council of Scientific and Industrial Research (CSIR), is known for its research and development related to various botanical disciplines. A broad spectrum of research activities is being conducted at CSIR-NBRI, which includes plant diversity, systematics and herbarium, pharmacognosy, phytochemistry, plant ecology, environmental technologies, molecular biology, biotechnology, plant genetic resources, plant conservation, and agro-technologies.

Masimo announced the findings of an observational, retrospective study published in Pediatrics International. In the study, researchers at the Osaka Women’s and Children’s Hospital in Japan found the Masimo EMMA® Portable Capnograph “useful for assessment of the respiratory condition in children with tracheostomy.” EMMA® provides seamless mainstream capnography for patients of all ages in a compact, easily portable device.

Max Healthcare Institute Ltd (MHC), India’s second largest private hospital chain operator by revenue in Fiscal 2020 announced the successful completion of its Qualified Institutions Placement (QIP). MHC raised INR 1,200 Cr (approx. USD 165 Mn) through its QIP, which saw participation from highly reputable global and domestic investors. MHC has accordingly issued 6,14,12,482 fresh equity shares of face value of INR 10 per equity share at a price of INR 195.40 per equity share.

The Subject Expert Committee (SEC) recommends DCGI to remove the Clinical Trial tag from Covaxin by Bharat Biotech which is Whole Virion, Inactivated Corona Virus Vaccine. And prior granted by DCGI under restricted use in emergency situation conditions.

Recommendations of the SEC meeting to examine COVID-19 related proposal under accelerated approval process made in its 146th meeting held on 10.03.2021 at CDSCO, HQ New Delhi.

UK’s National Health Services has approved world’s most expensive drug which is used to treat a rare genetic disorder. Manufactured by Novartis Gene Therapies, Zolgensma, has a reported list price of Rs 18 crore (£1.79 million) per dose, the NHS England said. The medicine is used to treat Spinal Muscular Atrophy (SMA), a rare and often fatal genetic disease that causes paralysis, muscle weakness and progressive loss of movement. Zolgensma will be used on babies and young children suffering the genetic disorder.

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies.